Ionis

Ionis is a drug discovery company that develops and commercializes ribonucleic acid-targeted therapeutics for cardiovascular and neurological diseases Read more

133 Followers on Owler
133 Followers on Owler
133 Followers on Owler
133 Followers on Owler

Ionis

Ionis is a drug discovery company that develops and commercializes ribonucleic acid-targeted therapeutics for cardiovascular and neurological diseases Read more

Brett P Monia's photo - CEO of Ionis

CEO

Brett P Monia

CEO Approval Rating

86/100

Founded:

1989

Status:

PublicIndependent CompanyNASDAQIONS

IONIS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Alnylam is one of Ionis's top competitors. Alnylam was founded in 2002, and its headquarters is in Cambridge, Massachusetts. Like Ionis, Alnylam also works within the Pharmaceuticals sector. Alnylam has 716 more employees than Ionis.

Arrowhead is Ionis's #2 rival. Arrowhead was founded in 1989 in Pasadena, California. Arrowhead operates in the Biotechnology industry. Arrowhead generates $618.4M less revenue than Ionis.

Sarepta is a top competitor of Ionis. Sarepta is a Public company that was founded in Cambridge, Massachusetts in 1980. Sarepta is in the Pharmaceuticals field. Sarepta has 129 more employees vs. Ionis.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Voyager a competitor of Ionis?

Ionis Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$707.5M

Ionis's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 1.3B. Over the last four quarters, Ionis's revenue has decreased by 23.3%. Specifically, in Q1 2021's revenue was $111.6M; in Q4 2020, it was $290.3M; in Q3 2020, it was $160.1M; in Q2 2020, Ionis's revenue was $145.5M.

Ionis Acquisitions

No recent acquisitions found related to Ionis

Ionis Funding History

Since Ionis was founded in 1989, it has participated in 2 rounds of funding. In total Ionis has raised $206.2M. Ionis' last funding round was on Dec 2015 for a total of $5.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series A
Dec 2015
$5M
-
Debt
Aug 2012
$201.3M
-

Since Ionis was founded in 1989, it has participated in 2 rounds of funding. In total Ionis has raised $206.2M. Ionis' last funding round was on Dec 2015 for a total of $5.0M

Ionis Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Aro Biotherapeutics is a pharmaceutical company that researches and develops protein therapeutics for the treatment of cancer and rare diseases.
$88M
Jan 04, 2021
Series A
-
Empirico develops a biotechnology platform that examines genomics data to develop drugs.
$17M
Jan 09, 2020
Series A
-

Ionis News

April 20, 2021MarketScreener

initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease

(marketscreener.com) CARLSBAD, Calif., April 20, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. to... See more »
April 8, 2021Markets Insider

Ionis prices private placement of convertible senior notes

CARLSBAD, Calif., April 8, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced ... See more »
April 8, 2021BioSpace

Non-profit Partnership Spurs Phase 3 Clinical Trial for Patients With Rare Genetic Form Of ALS

Ionis Pharmaceuticals announces pivotal patient trial of antisense therapy following aggressive joint... See more »
April 7, 2021Benzinga

Ionis Axes Akcea's 70% Workforce Under Restructuring Plan

Ionis Pharmaceuticals Inc (NASDAQ: IONS) said it expanded its distribution agreement with Swedish Orp... See more »
April 7, 2021FiercePharma

Ionis lays off majority of Akcea staff, expands Sobi Tegsedi deal

Ionis lays off majority of Akcea staff, expands Sobi Tegsedi deal bbulik Wed, 04/07/2021 - 10:01... See more »
April 6, 2021MarketScreener

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

(marketscreener.com) NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on... See more »
April 6, 2021Benzinga

Ionis Antisense Oligonucleotides To Be Evaluated With Progenity's Drug Delivery System

Progenity Inc (NASDAQ: PROG) has announced an agreement with Ionis Pharmaceuticals Inc (NASDAQ: IONS)... See more »

Ionis Press Releases

December 2, 2020PR Newswire

Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference

CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader... See more »
November 13, 2020PR Newswire

Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020

CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced ... See more »
November 10, 2020StreetInsider

Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference

CARLSBAD, Calif., Nov. 10, 2020 /PRNewswire/ --Â Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)Â announce... See more »
November 4, 2020StreetInsider

Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)

CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: ION... See more »
February 19, 2020centralcharts

Ionis Pharmaceuticals to hold 2019 financial results webcast

Ionis Pharmaceuticals to hold 2019 financial results webcast Webcast scheduled for Wednesday, Februar... See more »
December 12, 2019centralcharts

Ionis Pharmaceuticals announces private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024

Ionis Pharmaceuticals announces private placement of $507.5 million principal amount of 0.125% conver... See more »
December 2, 2019centralcharts

Ionis Pharmaceuticals to hold technology webcast

Ionis Pharmaceuticals to hold technology webcast Webcast scheduled for Friday, December 13th at 11:00... See more »

Ionis Videos

Social Media

Ionis Headquarters

2855 Gazelle Court

Carlsbad, California92010

1-760-931-9200

Driving Directions »

Trending Companies

Ionis Summary

ABOUT

Overview

Ionis is a drug discovery company that develops and commercializes ribonucleic acid-targeted therapeutics for cardiovascular and neurological diseases Ionis was founded in 1989. Ionis' headquarters is located in Carlsbad, California, USA 92010. It has...

CEO

Ionis's CEO, Brett P Monia, currently has an approval rating of 86%. Ionis's primary competitors are Alnylam, Arrowhead & Sarepta.

Website

ionispharma.com

Frequently Asked Questions about Ionis

  1. When was Ionis founded?

    Ionis was founded in 1989
  2. Who is Ionis's CEO?

    Ionis's CEO is Brett P Monia
  3. How much revenue does Ionis generate?

    Ionis generates $707.5M in revenue
  4. How much funding does Ionis have?

    Ionis has historically raised $206.3M in funding
  5. Where is Ionis's headquarters?

    Ionis's headquarters is in Carlsbad California, USA
  1. How many employees does Ionis have?

    Ionis has 737 employees
  2. What sector does Ionis operate in?

    Ionis is in Pharmaceuticals, Biotechnology
  3. Who are Ionis's competitors?

    Ionis's top competitors are Alnylam, Arrowhead, Sarepta
  4. Who has Ionis invested in?

    Ionis's has invested in companies such as Aro Biotherapeutics, Empirico